AbCellera Biologics (NASDAQ:ABCL) Coverage Initiated by Analysts at Lake Street Capital

AbCellera Biologics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Lake Street Capital initiated coverage of AbCellera Biologics with a Buy rating and a $19 price target, implying 72.26% upside from the prior close.
  • Analyst sentiment is broadly positive: the consensus rating is Moderate Buy, with an average price target of $16.75.
  • In its latest quarter, AbCellera reported a loss of $0.13 per share, better than the $0.17 loss analysts expected, and revenue of $10.64 million versus estimates of $8.42 million.
  • MarketBeat previews top five stocks to own in December.

Stock analysts at Lake Street Capital started coverage on shares of AbCellera Biologics (NASDAQ:ABCL - Get Free Report) in a research note issued to investors on Wednesday, Briefing.com reports. The firm set a "buy" rating and a $19.00 price target on the stock. Lake Street Capital's price target would suggest a potential upside of 72.26% from the company's previous close.

Several other analysts have also issued reports on ABCL. Stifel Nicolaus boosted their target price on shares of AbCellera Biologics from $9.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, November 10th. StoneX increased their price target on shares of AbCellera Biologics from $11.00 to $15.00 and gave the stock a "buy" rating in a research report on Wednesday, November 11th. The Goldman Sachs Group assumed coverage on shares of AbCellera Biologics in a research report on Thursday, September 24th. They issued a "neutral" rating and a $13.00 price target on the stock. Piper Sandler lifted their price target on shares of AbCellera Biologics from $12.00 to $20.00 and gave the stock an "overweight" rating in a research note on Monday. Finally, Jefferies Financial Group reissued a "buy" rating on shares of AbCellera Biologics in a research report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.75.

Read Our Latest Research Report on AbCellera Biologics

AbCellera Biologics Stock Down 0.8%

AbCellera Biologics stock opened at $11.03 on Wednesday. The business has a 50-day simple moving average of $12.32 and a two-hundred day simple moving average of $7.30. The company has a market cap of $3.60 billion, a P/E ratio of -22.98 and a beta of 1.59. AbCellera Biologics has a 52-week low of $2.74 and a 52-week high of $15.02.

AbCellera Biologics (NASDAQ:ABCL - Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.04. AbCellera Biologics had a negative net margin of 218.54% and a negative return on equity of 15.35%. The firm had revenue of $10.64 million during the quarter, compared to analyst estimates of $8.42 million. During the same quarter in the prior year, the firm earned ($0.19) EPS. Research analysts anticipate that AbCellera Biologics will post -0.65 EPS for the current fiscal year.

Insider Activity at AbCellera Biologics

In related news, major shareholder Holdings Ltd. Thermopylae acquired 60,565 shares of the stock in a transaction dated Thursday, November 12th. The shares were purchased at an average cost of $11.54 per share, with a total value of $698,920.10. Following the transaction, the insider directly owned 56,194,662 shares in the company, valued at approximately $648,486,399.48. This represents a 0.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 28.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On AbCellera Biologics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ABCL. Algert Global LLC purchased a new position in shares of AbCellera Biologics in the third quarter valued at about $643,000. Virtu Financial LLC purchased a new stake in shares of AbCellera Biologics during the third quarter worth about $305,000. Allworth Financial LP grew its position in shares of AbCellera Biologics by 37.6% during the third quarter. Allworth Financial LP now owns 16,024 shares of the company's stock worth $234,000 after purchasing an additional 4,381 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in AbCellera Biologics by 256.2% during the 3rd quarter. Goldman Sachs Group Inc. now owns 837,416 shares of the company's stock valued at $12,218,000 after purchasing an additional 602,289 shares during the period. Finally, Great Point Partners LLC purchased a new position in AbCellera Biologics in the 3rd quarter worth approximately $8,754,000. 61.42% of the stock is owned by hedge funds and other institutional investors.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.

Further Reading

Analyst Recommendations for AbCellera Biologics (NASDAQ:ABCL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbCellera Biologics Right Now?

Before you consider AbCellera Biologics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbCellera Biologics wasn't on the list.

While AbCellera Biologics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines